A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection

Hepatology

Volumn 63, Issue 2, 2016, Pages 634-643

  Dick, Travis B ^a   Lindberg, Lance S ^a   Ramirez, Debra D ^a   Charlton, Michael R ^a,b  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b Hepatology and Liver Transplantation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CALCINEURIN INHIBITOR;

DRUG INTERACTION; HEPATITIS C, CHRONIC; HUMAN; PRACTICE GUIDELINE;

ANTIVIRAL AGENTS; CALCINEURIN INHIBITORS; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84956759355     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27920     Document Type: Review

References (28)

1. US Food and Drug Administration. Preventable adverse reactions: a focus on drug interactions. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm110632.htm. Last updated June 18, 2014. Accessed January 2015.
2. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
3. Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics in drug-drug interactions. Curr Drug Targets 2011;12:600-620.
4. Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation 2005;111:230-239.
5. Olysio [package insert]. Titusville, NJ: Janssen Products; 2014.
6. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2015.
7. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2015.
8. Viekira Pak [package insert]. North Chicago, IL: AbbVie, Inc.; 2014.
9. Daklinza [package insert]. Anagni, Italy: Bristol-Myers Squibb; 2014.
10. Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz, and tenofovir. Antiviral Ther 2013;18:931-940.
11. German P, Garrison K, Phillip S. Drug-drug interactions between anti-HCV regimen ledipasvir/sofosbuvir and antiretrovirals. Presented at: CROI 2015. Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
12. Le Page C, Genin P, Baines MG, Hiscott J. Interferon activation and innate immunity. Rev Immunogenet 2000;2:374-386.
13. Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999;68:307-309.
14. Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Türler A, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004;10:939-944.
15. Kwo PY, Mantry P, Coackley E, Te HS, Vargas HE, Brown R Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;317:2375-2382.
16. van Maarseveen E, Crommelin H, Mudrikova T, van den Broek MPH, van Zuilen AD. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. Transplantation 2013;95:397-402.
17. Zortress [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2013.
18. Rapamune [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2012.
19. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274-287.
20. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:528-534.
21. Afhal N, Reddy R, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
22. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug. http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm. Published March 24, 2015. Accessed April 2015.
23. Tannenbaum C, Sheehan N. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol 2014;7:533-544.
24. Ouwerkerk-Mahadevan S, Sekar V, Simion A, Peeters M, Beaumont-Mauviel M. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers [Abstract]. Presented at: Infectious Diseases Week; October 17-21, 2012; San Diego, CA. Abstract 36620.
25. Copegus [package insert]. South San Francisco, CA: Genentech, Inc.; 2013.
26. Ramanathan S, Cheng A, Mittan A, Ebrahimi R, Kearney BP. Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. J Clin Pharmacol 2006;46:559-566.
27. Beumont-Mauviel M, Simion A, De Smedt G, Spittaels K, Peeters M, Sekar V. The pharmacokinetic interaction between the investigational NS3-4A HCV protease inhibitor TMC435 and methadone [Abstract]. Hepatology 2011;54(Suppl. 1):1000A. Abstract 1353.
28. Norvir [package insert]. North Chicago, IL: AbbVie, Inc.; 2013.